Kudura, K.; Ritz, N.; Kutzker, T.; Hoffmann, M.H.K.; Templeton, A.J.; Foerster, R.; Kreissl, M.C.; Antwi, K.
Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors. Cancers 2022, 14, 6095.
https://doi.org/10.3390/cancers14246095
AMA Style
Kudura K, Ritz N, Kutzker T, Hoffmann MHK, Templeton AJ, Foerster R, Kreissl MC, Antwi K.
Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors. Cancers. 2022; 14(24):6095.
https://doi.org/10.3390/cancers14246095
Chicago/Turabian Style
Kudura, Ken, Nando Ritz, Tim Kutzker, Martin H. K. Hoffmann, Arnoud J. Templeton, Robert Foerster, Michael C. Kreissl, and Kwadwo Antwi.
2022. "Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors" Cancers 14, no. 24: 6095.
https://doi.org/10.3390/cancers14246095
APA Style
Kudura, K., Ritz, N., Kutzker, T., Hoffmann, M. H. K., Templeton, A. J., Foerster, R., Kreissl, M. C., & Antwi, K.
(2022). Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors. Cancers, 14(24), 6095.
https://doi.org/10.3390/cancers14246095